ClinicaliQ Trial Snapshot
- A Study of Raludotatug Deruxtecan (R-DXd) in Subjects With Platinum-resistant, High-grade Ovarian, Primary Peritoneal, or Fallopian Tube Cancer — Recruiting • Phase II • Oncology • NCT06161025.
- Treatment being tested: Raludotatug deruxtecan (R-DXd), a novel targeted therapy designed to treat platinum-resistant high-grade ovarian, primary peritoneal, and fallopian tube cancers by combining antibody-drug conjugate technology to deliver cytotoxic agents directly to cancer cells.
- Patient eligibility overview: The study enrolls patients with platinum-resistant disease (cancers that recur within 6 months of platinum-based chemotherapy or are unresponsive to platinum), representing a high-risk population with limited treatment options and poor prognosis.
Use This Page For
- Quick orientation before opening the registry record.
- Checking recruitment status, phase and sponsor at a glance.
- Connecting this trial to nearby guidelines, Drug Science and education.
What This Trial Is Studying
This study will evaluate the safety and efficacy of R-DXd therapy in participants with ovarian, peritoneal, or fallopian tube cancer.
Eligibility Snapshot
- : * Sign and date the informed consent form prior to the start of any study-specific qualification procedures. * Age ≥18 years or the minimum legal adult age (whichever is greater) at the time the informed consent form is signed. * Participants with histologically or cytologically documented high-grade serous ovarian cancer (OVC), high-grade endometrioid OVC, primary peritoneal cancer, or fallopian tube cancer. * For Phase 2 (Part A) Participants must have at least 1 lesion, not previously irradiated, amenable to biopsy, and must consent to provide a pretreatment biopsy and on-treatment biopsy tissue sample (on-treatment biopsy sample not required for the Phase 3 part of the study). Fresh pretreatment biopsy may be waived for subjects who consent to provide an archival tumor tissue sample from a lesion not previously irradiated, performed within 6 months of consent and performed after treatment with their most recent cancer therapy regimen. * For Phase 2 (Part A): Has received at least 1 but no more than 3 prior systemic lines of anticancer therapy. For Phase 3 (Part B): Has received at least 1 but no more than 4 prior systemic lines of anticancer therapy: * Neoadjuvant +/-adjuvant considered 1 line of therapy. *…
Use the source registry for the full inclusion and exclusion criteria before discussing referral or enrolment.